Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 2:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Buprenorphine injection Clear all
Completed Phase 3 Interventional Results available

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

NCT02651584
View directory record Official record
Conditions
Opioid Use Disorders
Interventions
CAM2038 SC injection, SL BPN/NX tabs, placebo SC injections, SL placebo tablets
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 13, 2026, 2:30 AM EDT
Completed Phase 4 Interventional Results available

Analgesia After Total Shoulder Arthroplasty

NCT01782872
View directory record Official record
Conditions
Total Shoulder Arthroplasty
Interventions
Interscalene Block (ISB) - 0.375% Ropivacaine + additives, Interscalene Block (ISB) - 0.2% Ropivacaine + additives, Interscalene Block (ISB) - 0.1% Ropivacaine + additives, Interscalene Block (ISB) - Systemic Control
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 13, 2026, 2:30 AM EDT
Completed Phase 1 Interventional

Single-dose, Study of RBP-6000 in Opioid Dependent Individuals

NCT02765867
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2016 · Synced Sep 13, 2026, 2:30 AM EDT
Active, not recruiting Phase 2 Interventional

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

NCT04464980
View directory record Official record
Conditions
Opioid Use Disorder (OUD)
Interventions
SL-BUP, XR-BUP, XR-NTX, MM, MMR, MMD
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
21
States / cities
Little Rock, Arkansas • Tarzana, California • Bridgeport, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 13, 2026, 2:30 AM EDT
Terminated Phase 3 Interventional Results available

Virginia Opioid Overdose Treatment InitiatVE

NCT03818399
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
SUBLOCADE
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Sep 13, 2026, 2:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals

NCT01136356
View directory record Official record
Conditions
Opioid Abuse, Opioid Dependence
Interventions
buprenorphine, morphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 13, 2026, 2:30 AM EDT
Completed Phase 3 Interventional

Linking Hospitalized Injection Drug Users to Buprenorphine

NCT00987961
View directory record Official record
Conditions
Opiate Dependence
Interventions
Linkage
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 13, 2026, 2:30 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Interscalene Block With Liposomal Bupivacaine vs. Interscalene Block With Bupivacaine and Adjuvants

NCT03845894
View directory record Official record
Conditions
Shoulder Arthroplasty
Interventions
Liposomal bupivacaine, Bupivacaine with adjuvants
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 13, 2026, 2:30 AM EDT
Terminated No phase listed Observational

An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term

NCT04577144
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Online survey only
Other
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 13, 2026, 2:30 AM EDT
Completed Phase 3 Interventional Results available

Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine

NCT02357901
View directory record Official record
Conditions
Opioid Dependence, Opioid Related Disorders
Interventions
SUBOXONE, RBP-6000, Placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
38
States / cities
Haleyville, Alabama • Hamilton, Alabama • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 13, 2026, 2:30 AM EDT
Completed Phase 2 Interventional

Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)

NCT01708707
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Withdrawal Syndrome
Interventions
Buprenorphine, Morphine Sulfate
Drug
Lead sponsor
Pediatrix
Other
Eligibility
Up to 1 Year
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 13, 2026, 2:30 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Combined Injectable Treatment for HIV and OUD

NCT05991622
View directory record Official record
Conditions
Human Immunodeficiency Virus, Opioid Use Disorder
Interventions
Combined LAI Treatment: Cabenuva and Sublocade
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 13, 2026, 2:30 AM EDT
Not yet recruiting Phase 4 Interventional

Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic

NCT07176351
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 13, 2026, 2:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept

NCT03604159
View directory record Official record
Conditions
Opioid Dependence
Interventions
Buprenorphine Extended Release, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 13, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

A Multiple Dose Opioid Challenge Study

NCT02611752
View directory record Official record
Conditions
Moderate or Severe Opioid Use Disorder
Interventions
CAM2038
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Overland Park, Kansas • Lexington, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Sep 13, 2026, 2:30 AM EDT
Completed No phase listed Observational

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

NCT03911466
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 13, 2026, 2:30 AM EDT
Not listed Not applicable Interventional

Serratus Anterior Plane Block With and Without Adjuvants in Video-assisted Thoracoscopy

NCT05090761
View directory record Official record
Conditions
Post Operative Pain, Acute
Interventions
Bupivacaine 0.25% Injectable Solution, Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pontiac, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Sep 13, 2026, 2:30 AM EDT
Not listed Not applicable Interventional

Are Superficial Parasternal Intercostal Plane (SPIP) Blocks With Bupivacaine and With or Without Adjuvants Helpful for Post-operative Pain After Coronary Artery Bypass Grafting?

NCT05003765
View directory record Official record
Conditions
Post-operative Pain Management
Interventions
Bupivacaine 0.25% Injectable Solution, Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pontiac, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Sep 13, 2026, 2:30 AM EDT
Completed No phase listed Observational

An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery

NCT03604861
View directory record Official record
Conditions
Opioid-use Disorder, Opioid-related Disorders
Interventions
Not applicable - no defined intervention
Other
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
35
States / cities
Haleyville, Alabama • Hamilton, Alabama • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 13, 2026, 2:30 AM EDT
Completed Phase 3 Interventional Results available

Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

NCT02537574
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
NTX/BUP, NTX/PBO-B, PBO-N/PBO-B
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
20
States / cities
Oceanside, California • Orange, California • Lauderhill, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 13, 2026, 2:30 AM EDT
Completed Phase 2Phase 3 Interventional

EXHIT ENTRE Comparative Effectiveness Trial

NCT04345718
View directory record Official record
Conditions
Substance Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
Extended Release Buprenorphine, Treatment as Usual
Drug
Lead sponsor
Gavin Bart
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 13, 2026, 2:30 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

NCT06854029
View directory record Official record
Conditions
HIV Infections, Opioid Use Disorder, Incarceration; Lens
Interventions
Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 13, 2026, 2:30 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

NCT05704543
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine Extended-Release Injection
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
6
States / cities
San Diego, California • Hollywood, Florida • Miami Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 13, 2026, 2:30 AM EDT
Terminated Phase 2 Interventional Results available

Monthly Injectable BUP for MA Use Disorder (MURB) Trial

NCT05283304
View directory record Official record
Conditions
Methamphetamine-dependence
Interventions
Buprenorphine injection (BUP-Inj), Placebo injection
Drug · Other
Lead sponsor
Madhukar H. Trivedi, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Tulsa, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 13, 2026, 2:30 AM EDT